The increased titres and productivity of the latest generation of cell lines are now well documented and understood. The rate limiting steps and capacity constraints within biopharmaceutical production have now moved to the downstream arena. This meeting combines both users and suppliers to provide an insight into how these constraints are being addressed by the industry as a whole.